NFKB1 and head and neck squamous cell carcinoma: Diseases for which NF-κB inhibition via p65 or p50 siRNA may be considered include rheumatoid arthritis [156], osteoarthritis [157], esophageal cancer [158], head and neck squamous cell carcinoma [159,160], colorectal cancer [161], and myelodysplastic syndrome [162].